MR Molecular Imaging of Extradomain-B Fibronectin for Assessing Progression and Therapy Resistance of Prostate Cancer is a research paper published in Chemical & Biomedical Imaging (2024). On theSindex it has a DataRank of 0.345. It has been cited 9 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.345
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Cancer Institute
Grant: R01 CA211762
National Cancer Institute
Grant: R44 CA265626
NCI NIH HHS
Grant: P30 CA043703
National Institutes of Health
Grant: 1R44CA265626-01A1
Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer
National Institutes of Health
Grant: 3P30CA043703-20S1
Case Comprehensive Cancer Center Support Grant
National Institutes of Health
Grant: 1R01CA211762-01A1
Targeted MRI contrast agents for differential diagnosis of prostate cancer
FWCI
2.55
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals